Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 30, 2013. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting held on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share capital movements.
- Shares Purchased: 780,000 Ordinary Shares of 25 pence each.
- Purchase Date: May 30, 2013.
- Price Range: Highest price paid was 1,738.5 pence per share; lowest price paid was 1,710.0 pence per share.
- Treasury Holdings (Settled): 502,067,012 shares (9.25% of total issued share capital).
- Treasury Holdings (Including Unsettled): 503,939,012 shares (10.23% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,926,846,123 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 780,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.23% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of shares in issue (4,926,846,123) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current Treasury share count and its impact on total voting rights (10.23% including unsettled shares).
- Note that the repurchase was executed within the price range of 1,710.0 to 1,738.5 pence per share.